(0.06%) 5 540.25 points
(-0.10%) 39 488 points
(0.23%) 20 018 points
(0.92%) $81.57
(-2.10%) $2.70
(-0.42%) $2 321.00
(0.25%) $28.94
(1.24%) $998.60
(0.29%) $0.936
(0.21%) $10.63
(0.21%) $0.790
(-0.28%) $87.25
-3.08% $ 0.126
Live Chart Being Loaded With Signals
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers...
Stats | |
---|---|
Tagesvolumen | 135 947 |
Durchschnittsvolumen | 108 675 |
Marktkapitalisierung | 3.29M |
EPS | $-1.280 ( Q1 | 2023-05-22 ) |
Last Dividend | $0.139 ( 2023-12-26 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0362 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00400 (3.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-06 | Shea Brian J. | Sell | 0 | Common Stock |
2023-06-06 | Shea Brian J. | Sell | 15 000 | Employee Stock Option (right to buy) |
2023-06-06 | Shea Brian J. | Sell | 3 744 | Employee Stock Option (right to buy) |
2023-06-06 | Shea Brian J. | Sell | 14 700 | Employee Stock Option (right to buy) |
2023-06-06 | Shea Brian J. | Sell | 19 100 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
-62.73 |
Last 97 transactions |
Buy: 2 441 000 | Sell: 694 654 |
Volumen Korrelation
Oncorus, Inc. Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Oncorus, Inc. Korrelation - Währung/Rohstoff
Oncorus, Inc. Finanzdaten
Annual | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-3.02 |
FY | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-3.02 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-2.56 |
FY | 2020 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-9.35 |
Financial Reports:
No articles found.
Oncorus, Inc. Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.139 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.139 | 2023-12-26 |
Last Dividend | $0.139 | 2023-12-26 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.139 | -- |
Avg. Dividend % Per Year | 16.67% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.139 | 50.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
26 Dec 2023 | $0.139 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.681 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.306 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.500 | 0.800 | 7.50 | 6.00 | [1 - 3] |
quickRatioTTM | 1.446 | 0.800 | 6.20 | 4.96 | [0.8 - 2.5] |
cashRatioTTM | 0.682 | 1.500 | 7.32 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.631 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 52.09 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.626 | 2.00 | -0.542 | -1.084 | [0 - 30] |
freeCashFlowPerShareTTM | -2.14 | 2.00 | -1.071 | -2.14 | [0 - 20] |
debtEquityRatioTTM | 2.23 | -1.500 | 1.099 | -1.649 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.613 | 1.000 | -4.52 | -4.52 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.437 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0440 | 1.000 | -0.105 | 0 | [1 - 100] |
returnOnEquityTTM | -1.306 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.14 | 2.00 | -0.714 | -2.14 | [0 - 30] |
dividendYielPercentageTTM | 110.58 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.626 | 2.00 | -0.542 | -1.084 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.000202 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.012 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Oncorus, Inc.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.